AAV-mediated knockdown of Peripherin-2 in vivo using miRNA-based hairpins

Gene Therapy

Volumn 17, Issue 4, 2010, Pages 486-493

  Georgiadis, A ^a   Tschernutter, M ^a   Bainbridge, J W B ^a   Robbie, S J ^a   McIntosh, J ^b   Nathwani, A C ^b   Smith, A J ^a   Ali, R R ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

AAV; MiRNA; Prph2; Rds; Retinal degeneration; RNAi

Indexed keywords

MICRORNA; PARVOVIRUS VECTOR; PERIPHERIN; SHORT HAIRPIN RNA;

ADENO ASSOCIATED VIRUS; ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EMBRYO; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GENE TARGETING; GENE THERAPY; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PHOTORECEPTOR; PHOTORECEPTOR CELL; PRIORITY JOURNAL; RETINA DEGENERATION; RETINA MACULOPATHY; RETINITIS PIGMENTOSA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; BASE PAIRING; BASE SEQUENCE; BLOTTING, WESTERN; DEPENDOVIRUS; DNA PRIMERS; GENE THERAPY; IMMUNOHISTOCHEMISTRY; INTERMEDIATE FILAMENT PROTEINS; MEMBRANE GLYCOPROTEINS; MICE; MICRORNAS; MOLECULAR SEQUENCE DATA; NERVE TISSUE PROTEINS; RETINAL DEGENERATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE;

MURINAE;

EID: 77950863181     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2009.162     Document Type: Article

References (40)

1. Bessant DA, Ali RR, Bhattacharya SS. Molecular genetics and prospects for therapy of the inherited retinal dystrophies. Curr Opin Genet Dev 2001; 11: 307-316.
2. Daiger SP, Bowne SJ, Sullivan LS. Perspective on genes and mutations causing retinitis pigmentosa. Arch Ophthalmol 2007; 125: 151-158.
3. Farrar GJ, Kenna PF, Humphries P. On the genetics of retinitis pigmentosa and on mutation-independent approaches to therapeutic intervention. EMBO J 2002; 21: 857-864.
4. Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet 2006; 368: 1795-1809.
5. Smith AJ, Bainbridge JW, Ali RR. Prospects for retinal gene replacement therapy. Trends Genet 2009; 25: 156-165.
6. Travis GH, Sutcliffe JG, Bok D. The retinal degeneration slow (rds) gene product is a photoreceptor disc membrane-associated glycoprotein. Neuron 1991; 6: 61-70.
7. Boon CJ, den Hollander AI, Hoyng CB, Cremers FP, Klevering BJ, Keunen JE. The spectrum of retinal dystrophies caused by mutations in the peripherin/RDS gene. Prog Retin Eye Res 2008; 27: 213-235.
8. Hamel CP. Cone rod dystrophies. Orphanet J Rare Dis 2007; 2: 7.
9. Musarella MA. Molecular genetics of macular degeneration. Doc Ophthalmol 2001; 102: 165-177.
10. Sohocki MM, Daiger SP, Bowne SJ, Rodriquez JA, Northrup H, Heckenlively JR et al. Prevalence of mutations causing retinitis pigmentosa and other inherited retinopathies. Hum Mutat 2001; 17: 42-51.
11. Sullivan LS, Bowne SJ, Birch DG, Hughbanks-Wheaton D, Heckenlively JR, Lewis RA et al. Prevalence of disease-causing mutations in families with autosomal dominant retinitis pigmentosa: a screen of known genes in 200 families. Invest Ophthalmol Vis Sci 2006; 47: 3052-3064.
12. Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008; 358: 2231-2239.
13. Hauswirth WW, Aleman TS, Kaushal S, Cideciyan AV, Schwartz SB, Wang L et al. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adenoassociated virus gene vector: short-term results of a phase I trial. Hum Gene Ther 2008; 19: 979-990.
14. Maguire AM, Simonelli F, Pierce EA, Pugh Jr EN, Mingozzi F, Bennicelli J et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008; 358: 2240-2248.
15. Bantounas I, Glover CP, Kelly S, Iseki S, Phylactou LA, Uney JB. Assessing adenoviral hammerhead ribozyme and small hairpin RNA cassettes in neurons: inhibition of endogenous caspase-3 activity and protection from apoptotic cell death. J Neurosci Res 2005; 79: 661-669.
16. Drenser KA, Timmers AM, Hauswirth WW, Lewin AS. Ribozyme-targeted destruction of RNA associated with autosomal- dominant retinitis pigmentosa. Invest Ophthalmol Vis Sci 1998; 39: 681-689.
17. Gorbatyuk M, Justilien V, Liu J, Hauswirth WW, Lewin AS. Preservation of photoreceptor morphology and function in P23H rats using an allele independent ribozyme. Exp Eye Res 2007; 84: 44-52.
18. Lavail MM, Yasumura D, Matthes MT, Drenser KA, Flannery JG, Lewin AS et al. Ribozyme rescue of photoreceptor cells in P23H transgenic rats: long-term survival and late-stage therapy. Proc Natl Acad Sci USA 2000; 97: 11488-11493.
19. Lewin AS, Drenser KA, HauswirthWW, Nishikawa S, Yasumura D, Flannery JG et al. Ribozyme rescue of photoreceptor cells in a transgenic rat model of autosomal dominant retinitis pigmentosa. Nat Med 1998; 4: 967-971.
20. Tessitore A, Parisi F, Denti MA, Allocca M, Di Vicino U, Domenici L et al. Preferential silencing of a common dominant rhodopsin mutation does not inhibit retinal degeneration in a transgenic model. Mol Ther 2006; 14: 692-699.
21. Gorbatyuk M, Justilien V, Liu J, Hauswirth WW, Lewin AS. Suppression of mouse rhodopsin expression in vivo by AAV mediated siRNA delivery. Vision Res 2007; 47: 1202-1208.
22. O'Reilly M, Palfi A, Chadderton N, Millington-Ward S, Ader M, Cronin T et al. RNA interference-mediated suppression and replacement of human rhodopsin in vivo. Am J Hum Genet 2007; 81: 127-135.
23. O'Reilly M, Millington-Ward S, Palfi A, Chadderton N, Cronin T, McNally N et al. A transgenic mouse model for gene therapy of rhodopsin-linked retinitis pigmentosa. Vision Res 2008; 48: 386-391.
24. Palfi A, Ader M, Kiang AS, Millington-Ward S, Clark G, O'Reilly M et al. RNAi-based suppression and replacement of rdsperipherin in retinal organotypic culture. Hum Mutat 2006; 27: 260-268.
25. Tam LC, Kiang AS, Kennan A, Kenna PF, Chadderton N, Ader M et al. Therapeutic benefit derived from RNAi-mediated ablation of IMPDH1 transcripts in a murine model of autosomal dominant retinitis pigmentosa (RP10). Hum Mol Genet 2008; 17: 2084-2100.
26. Chadderton N, Millington-Ward S, Palfi A, O'Reilly M, Tuohy G, Humphries MM et al. Improved retinal function in a mouse model of dominant retinitis pigmentosa following AAV-delivered gene therapy. Mol Ther 2009; 17: 593-599.
27. Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, Davis CR et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006; 441: 537-541.
28. Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, Mao M et al. Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 2003; 21: 635-637.
29. Kim VN. MicroRNA precursors in motion: exportin-5 mediates their nuclear export. Trends Cell Biol 2004; 14: 156-159.
30. McBride JL, Boudreau RL, Harper SQ, Staber PD, Monteys AM, Martins I et al. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci USA 2008; 105: 5868-5873.
31. Shan Z, Lin Q, Deng C, Li X, Huang W, Tan H et al. An efficient method to enhance gene silencing by using precursor microRNA designed small hairpin RNAs. Mol Biol Rep 2008; 36: 1483-1489.
32. Boudreau RL, Martins I, Davidson BL. Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo. Mol Ther 2009; 17: 169-175.
33. Cashman SM, Binkley EA, Kumar-Singh R. Towards mutationindependent silencing of genes involved in retinal degeneration by RNA interference. Gene Therapy 2005; 12: 1223-1228.
34. Boden D, Pusch O, Silbermann R, Lee F, Tucker L, Ramratnam B. Enhanced gene silencing of HIV-1 specific siRNA using microRNA designed hairpins. Nucleic Acids Res 2004; 32: 1154-1158.
35. Ali RR, Sarra GM, Stephens C, Alwis MD, Bainbridge JW, Munro PM et al. Restoration of photoreceptor ultrastructure and function in retinal degeneration slow mice by gene therapy. Nat Genet 2000; 25: 306-310.
36. Paskowitz DM, Greenberg KP, Yasumura D, Grimm D, Yang H, Duncan JL et al. Rapid and stable knockdown of an endogenous gene in retinal pigment epithelium. Hum Gene Ther 2007; 18: 871-880.
37. Xia H, Mao Q, Eliason SL, Harper SQ, Martins IH, Orr HT et al. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med 2004; 10: 816-820.
38. Natkunarajah M, Trittibach P, McIntosh J, Duran Y, Barker SE, Smith AJ et al. Assessment of ocular transduction using singlestranded and self-complementary recombinant adeno-associated virus serotype 2/8. Gene Therapy 2008; 15: 463-467.
39. Ali RR, Reichel MB, Thrasher AJ, Levinsky RJ, Kinnon C, Kanuga N et al. Gene transfer into the mouse retina mediated by an adeno-associated viral vector. Hum Mol Genet 1996; 5: 591-594.
40. Tschernutter M, Schlichtenbrede FC, Howe S, Balaggan KS, Munro PM, Bainbridge JW et al. Long-term preservation of retinal function in the RCS rat model of retinitis pigmentosa following lentivirus-mediated gene therapy. Gene Therapy 2005; 12: 694-701.